SLAMF7 (CD319) is a robust marker of malignant plasma cells in multiple myeloma and was shown to be responsible for the phagocytosis of cells after disruption of the tumor surveillance checkpoint CD47-SIRPα. Here, SLAMF7 is linked to plasma cell myeloma.